Patent Application
20190070342
The present invention relates generally to patches for vessel and organ repair and drug delivery, including free-standing biodegradable patches.
As some of the leading causes of death in the United States, cardiovascular diseases affect millions. Some diseases result in the weakening of blood vessels, while others result from the stenosis of a blood vessel. Stents have been used to provide support and drug-delivery to these blood vessels, but stent implantation carries a number of risks. For example, blood clots may develop at the site of the stent as the body rejects the foreign object, or the stent itself may migrate or fracture. As such, alternative methods of providing support to weakened blood vessels may be desirable.
Another prominent cause of cardiac ischemia and stroke is the occurrence of vulnerable plaque deposits that can accumulate within an individual's vasculature. Such plaque deposits result when a lipid pool forms beneath a thin fibrous cap along the lining of a vessel. When subjected to increased rates of hemodynamic pulsating expansion during systole and elastic contraction during diastole associated with excessive exercise, high mechanical stresses may form in the fibrous cap. Such stresses may lead to rupture of the fibrous cap, releasing a shower of potentially life-threatening emboli into the patient's vasculature. It would therefore be desirable to provide apparatus and methods for isolating and treating vulnerable plaques, so as to minimize the risk of sudden rupture.
A number of solutions have been proposed in the prior art for treating weakened vessels and vulnerable plaques, often involving the placement of a stent within the vessel, with or without a drug-eluting coating. Most stents employ a metal alloy framework, which may include a drug-eluting coating. As noted above, the use of metal stents can introduce additional long-term concerns for patients, including the occurrence of endothelial hyperplasia at the ends of the stent, fatigue fracture and stent migration. More recently, drug-eluting coatings have been employed on some stent designs to reduce the incidence of restenosis, although long-term reduction of restenosis using such coatings has yet to be achieved.
In addition, some previously-known stents have sought to employ naturally occurring biodegradable materials, such as fibrin, or synthetic polymers, such as polyglycolic acid. For example, U.S. Pat. No. 5,510,077 to Dinh et al. describes a stent cast from fibrin by charging a solution of fibrinogen and a fibrinogen-coagulating protein, such as thrombin, in liquid form into a mold cavity containing a metal alloy frame, so as to form a fibrin-coated stent when the fibrin cures. That patent discloses that synthetic polymers, and/or drugs, additionally may be mixed and cross-linked with the fibrinogen and thrombin to improve tissue ingrowth and neointimal formation as the fibrin degrades. However, the patent does not alleviate concerns regarding the fate of the metal alloy frame once the fibrin fully degrades. Moreover, it is believed that such coatings may be relatively fragile, and therefore subject to cracking and delamination resulting from bending and torsional stresses applied to the metal alloy frame in situ.
U.S. Pat. No. 5,591,224 to Schwartz et al. and U.S. Pat. No. 6,312,457 to DiMatteo et al. attempt to overcome the shortcomings of the previously-known devices, such as those described in the Dinh patent, using a support structure formed of elastin, polyglycolic acid or other biodegradable polymer instead of a metal alloy frame. DiMatteo also describes that a fibrin layer on the exterior of the device may be used as an adhesive to adhere the device to the vessel wall. Such materials, however, can be relatively difficult to handle and to deliver within the vasculature using conventional delivery systems, and accordingly no commercially practicable products have been realized using such constructions. Likewise, U.S. Pat. No. 7,399,483 to Stimmeder describes compositions suitable for tissue gluing, sealing or hemostasis, in which a composition of solid fibrinogen and solid thrombin is disposed on a biodegradable carrier, such as a collagen sponge. Such products are not intended for intravascular use and continue to require some form of support structure.
A number of previously known systems have been investigated that could enable an adhesive-coated stent or vascular patch to be delivered intravascularly. For example, U.S. Pat. No. 7,044,982 to Millbocker describes methods of repairing internal defects involving an adhesive-coated prosthetic in which the adhesive is encapsulated within a water soluble material so as to be non-adhesive until the prosthetic is placed in contact with tissue. U.S. Pat. No. 7,402,172 to Chin et al. describes an adhesive-coated intraluminal therapeutic patch having a water soluble coating and a slidable sheath disposed on the delivery catheter to prevent premature activation of the adhesive. To date, the systems described in the foregoing patents do not appear to have overcome the problems inherent in intravascularly delivering an adhesive patch without premature or incomplete activation of the adhesive.
Allergic rhinitis is a symptomatic disorder of the nose induced after allergen exposure due to an IgE-mediated inflammation of membranes lining the nose. It is clinically defined as a symptomatic condition with four major symptoms: anterior or posterior rhinorrhea, sneezing, nasal itching and nasal congestion. Allergic rhinitis symptoms result in sleep disturbance, fatigue, depressed mood and cognitive function compromise that impair quality of life and productivity. Allergic rhinitis may be associated with conjunctivitis, postnasal drip, Eustachian tube dysfunction, otitis media, sinusitis, dental malocclusions, and facial deformities. Triggers of allergic rhinitis may include domestic allergens such as mites, domestic animals, insects, or of plant origin; common outdoor allergens such as pollens and molds; occupational triggers such as latex; tobacco smoke; automobile exhaust such as ozone, oxides of nitrogen, and sulphur dioxide; aspirin and other non-steroidal anti-inflammatory drugs.
Allergic rhinitis affects 30 million to 60 million people in the United States annually, including 10% to 30% of adults and as many as 40% of children. The cost of treating allergic rhinitis is substantial, and increases commensurately with disease severity and comorbidities. The overall costs of treating allergic rhinitis in the United States in 2005 were estimated at $11.2 billion, nearly double the $6.1 billion spent in 2000 (in 2005 dollars); more than half was spent on prescription medications. The total direct medical cost of allergic rhinitis was estimated at $3.4 billion, with most attributable to prescription medications (46.6%) and outpatient visits (51.9%).
Nasal polyps are inflammatory outgrowths of sinonasal tissue that are estimated to occur in 1% to 4% of the U.S. general population. Although nasal polyps are observed in various clinical conditions including cystic fibrosis and malignancy, they are more frequently associated with a subset of chronic rhinosinusitis (CRS) aptly named chronic rhinosinusitis with nasal polyps (CRSwNP). In this condition, nasal polyps are benign and typically develop bilaterally in the sinonasal cavity. Among all patients with CRS, only approximately 25% to 30% have CRSwNP. However, CRSwNP is associated with significant morbidity and decreased quality of life, making this disease clinically important to identify, evaluate, and treat.
In addition to the direct medical costs resulting from those nasal symptoms and conditions, there also are other hidden direct or indirect costs resulting from days off from work and poor productivity. For example, in one study that evaluates the economic impact of illness on productivity from the employer's perspective, allergic rhinitis accounted for greater loss of productivity (23% of all lost productivity) than any other illness. It is believed that the total allergic rhinitis costs (direct, hidden direct, and indirect) are higher than those attributed to asthma, cancer, diabetes mellitus, and migraines.
Conventional medical therapies for allergic rhinitis, CRS, and CRSwNP include oral and/or topical formulations containing therapeutic agents such as antihistamines, corticosteroids, and leukotriene receptor antagonists. Biologic medications, such as monoclonal antibodies are also available. However, conventional medical therapies suffer from a low clinical efficacy due to the lack of methods of administration that efficiently deliver the drugs to the pathogenic sites inside a patient's nasal cavities and/or nearby tissues. Conventional methods, dosage forms, and devices for localized delivery to the nasal cavity and nearby tissues are often invasive and/or require surgical operations, and are less preferred due to the associated risks and costs. More recently, minimally-invasive apparatuses or implants have been used to deliver therapeutic agents or drugs into a patient's sinus cavity. For example, the Resolve apparatus by Intersect ENT is an umbrella-shaped, steroid-releasing implant with eight arms designed to facilitate opening of the sinus cavity without the need for surgical tissue resection. However, the device is not biodegradable or bioabsorbable, and needs to be removed after use.
Further, patient compliance remains a significant issue that negatively affects the clinical efficacy of conventional therapies, which often require long-term and frequent applications of the medication. Also, side effects due to the systemic exposure to the drug, or due to the use of nasal sprays and nebulizers, and other issues related to intranasal formulations such as nasal irritation and unacceptable tastes or odors, further complicate the use of the conventional medications. Despite the monetary and time costs of the conventional therapies, and the conditions' effects on patients' quality of life, a study showed that 64% of the patients do not adhere to their medication regimens.
In view of the foregoing, the present invention is directed to methods and apparatus for providing a free-standing biodegradable patch suitable for medical applications, especially intravascular, intra-nasal, minimally-invasive, and intraoperative surgical applications. In one preferred embodiment, the patch comprises a free-standing film or device comprising a mixture of a solid fibrinogen component and a solid thrombin component that, when exposed to an aqueous environment, undergoes polymerization to form fibrin. The solid fibrinogen and thrombin components may comprise a mixture that forms a continuous layer or may be divided into a plurality of discrete segments. Alternatively, the solid fibrinogen and solid thrombin components may comprise separate layers. The patch may comprise only solid fibrinogen, or solid fibrinogen with a calcium chloride, but without a thrombin component. In accordance with one aspect of the invention, the film or device may take a non-adherent form during delivery to a target location within a vessel or tissue, and thereafter activated to adhere to a vessel wall or tissue.
A patch constructed in accordance with the principles of the present invention may include one or more polymers added to the solid fibrinogen and, if present, thrombin components to improve the mechanical properties of the patch, such as strength and/or flexibility. The patch of the present invention optionally may include one or more additional agents or additives, e.g., Factor XIII, inorganic calcium salts, a plasticizer, radiopaque material, etc. The patch of the present invention may include one or more therapeutic drugs, genes, or other bioactive agents that elute from the patch into the adjacent tissue or vessel, or are delivered to the surrounding tissue or bloodstream during biodegradation of the patch.
The patch may be configured for intravascular or minimally-invasive surgical applications to be delivered using an expandable member (e.g., a balloon, cage, or other expandable structure), such that the expandable member may be expanded in situ to place the patch in apposition with tissue or vessel wall. In other embodiments, the patch may be coated or cast directly onto the expandable member. In accordance with another aspect of the invention, a protective layer may be used to temporarily adhere the patch to an expandable member or a protective layer may be applied directly to the exterior of the patch.
In accordance with one aspect of the present invention, the patch may be disposed on an expandable member such that only those portions of the patch that contact a tissue or vessel wall by expansion of an expandable member adhere to the tissue or vessel wall, while non-contacting portions remain affixed to the expandable member. In this manner, the patch may be used to provide a protective layer to the inner lumen of a vessel in the vicinity of a vessel bifurcation without occluding a branch vessel. Methods of making and using a free-standing biodegradable patch in accordance with the present invention are also provided.
In accordance to one aspect of the present invention, a method for treating a nasal condition, e.g., an infectious condition, an allergic condition, an inflammatory condition, a physical wound or lesion, and any combination thereof, in a subject are provided. The method includes administering a biocompatible film into a nasal cavity of the subject, e.g., the nasal passageway, ethmoid sinus, frontal sinus, sphenoid sinus, maxillary sinus, or any combination thereof, the biocompatible film integrally formed, prior to adherence to the tissue, of at least a first adhesive layer adjoined to a second layer having at least one therapeutic agent. For example, the administration of the biocompatible film may be performed trans-nasally, and the method may be performed during a nasal or sinus surgery.
The therapeutic agent may include corticosteroids, antihistamines, monoclonal antibodies, leukotriene receptor antagonists, anti-inflammatory cytokines, vasoconstrictive agents, and any combination thereof. For example, the corticosteroids may include amcinonide, betamethasone benzoate, betamethasone dipropionate, betamethasone valerate, clobetasol propionate, clocortolone pivalate, desonide, desoximetasone, dexamethasone, dexamethasone sodium phosphate, diflorasone diacetate, fluocinonide, fluocinolone acetonide, flurandrenolide, fluticasone propionate, halcinonide, halobetasol propionate, hydrocortisone, hydrocortisone butyrate, hydrocortisone valerate, mometasone furoate, prednisolone acetate, triamcinolone acetonide, and any combination thereof.
The biocompatible film releases a pharmaceutically effective amount of the therapeutic agent upon administration to the nasal cavity, such that the pharmaceutically effective amount of the therapeutic agent is sufficient to treat at least one of rhinitis, rhinosinusitis, or nasal polyps. In addition, the biocompatible film is free-standing without a support structure. The biocompatible film also may be biodegradable and designed to release the therapeutic agent in a controlled fashion. The biocompatible film further may include solid fibrinogen. In accordance with one aspect of the present invention, the biocompatible film is micronized and administered in a powdered form.
In accordance with one aspect of the present invention, the nasal condition is allergic rhinitis or chronic rhinosinusitis with nasal polys, and the therapeutic agent is fluticasone propionate or mometasone furoate. Upon administration of the biocompatible film, the biocompatible film forms an adhesive patch in a vicinity of a pathogenic site in the nasal cavity. For example, the pathogenic site may be on or around the inferior turbinate of the nasal cavity, on or around the inferior meatus of the nasal cavity, on or around nasal polyps, on the nasal or sinus mucosa, or any combination thereof.
In accordance with yet another aspect of the present invention, a pharmaceutical dosage form for treating a nasal condition in a subject is provided. The pharmaceutical dosage form includes a biocompatible film integrally formed, prior to adherence to the tissue, of at least a first adhesive layer adjoined to a second layer that carries a therapeutic agent. The therapeutic agent may include corticosteroids, antihistamines, monoclonal antibodies, leukotriene receptor antagonists, anti-inflammatory cytokines, vasoconstrictive agents, and any combination thereof.
The biocompatible film is sized and shaped for delivery into a nasal cavity of the subject. In addition, the biocompatible film releases the therapeutic agent in a controlled fashion in the nasal cavity sufficient to treat at least one of rhinitis, rhinosinusitis, or nasal polyps. For example, the biocompatible film may be biodegradable such that the biocompatible film releases the therapeutic agent while the biocompatible film biodegrades. In one embodiment, the biocompatible film includes solid fibrinogen, and forms an adherent patch upon exposure to moisture. The pharmaceutical dosage form may include a plurality of the biocompatible films, wherein each of the biocompatible films carries a unit dose of the therapeutic agent. For example, the unit doses carried by each of the plurality of the biocompatible films may be the same or different.
In accordance with yet another aspect of the present invention, a kit for treating a nasal condition in a subject is provided. The kit includes a biocompatible film integrally formed, prior to adherence to the tissue, of at least a first adhesive layer adjoined to a second layer having a therapeutic agent, and a delivery device for advancing and deploying the biocompatible film into a nasal cavity of the subject. For example, the therapeutic agent includes corticosteroids, antihistamines, monoclonal antibodies, leukotriene receptor antagonists, anti-inflammatory cytokines, vasoconstrictive agents, and any combination thereof. The biocompatible film is free-standing without a support structure when deployed in the nasal cavity, and releases the therapeutic agent in a controlled fashion when deployed in the nasal cavity sufficient to treat at least one of rhinitis, rhinosinusitis, or nasal polyps.
In accordance with one aspect of the present invention, the biocompatible film is micronized and administered in a powdered form. For example, the delivery device may include an expandable member having a surface designed to be coated with the micronized biocompatible film, and a catheter in fluidic communication with the expandable member, wherein the catheter inflates the expandable member such that the surface of the expandable member contacts the nasal cavity of the subject thereby transferring the micronized biocompatible film to the nasal cavity of the subject. In another embodiment, the delivery device may include an expandable member having a surface, the surface having a plurality of holes sized and shaped to be sealed with the micronized biocompatible film when the expandable member is in a deflated state, and a catheter in fluidic communication with the expandable member. The catheter inflates the expandable member such that pressure within the expandable member causes the micronized biocompatible film to be transferred from the surface of the expandable member to the nasal cavity of the subject.
In yet another embodiment, the delivery device may include an airbrush-like dispenser. For example, the airbrush-like dispenser includes a hollow elongated member having a dispensing tip and an air inlet, a cartridge in communication with the hollow elongated member and sized and shaped to house the micronized biocompatible film, a source of pressurized air in fluidic communication with the air inlet, and a trigger that may be actuated by a user. The cartridge selectively introduces the micronized biocompatible film into the hollow elongated member such that upon actuation of the trigger, pressured air is introduced into the hollow elongated member via the air inlet to transfer the micronized biocompatible film to the nasal cavity of the subject via the dispensing tip.
In accordance with one aspect of the present invention, the biocompatible film is micronized and administered in a rod form. In such an embodiment, the delivery device includes a first open end, a second open end, and a lumen extending therebetween, the lumen sized and shaped to accept the micronized biocompatible film, a cartridge in communication with the lumen and sized and shaped to house the micronized biocompatible film, and a plunger moveable between the first end and the second end within the lumen, wherein the plunger may be actuated by a user. The cartridge selectively introduces the micronized biocompatible film into the lumen such that upon actuation of the plunger, the plunger transfers the micronized biocompatible film to the nasal cavity of the subject via the second end.
The present invention is generally directed to a free-standing biodegradable patch for use in medical procedures tor supporting, protecting or joining weakened tissue or vessels, including interventional, minimally-invasive and intraoperative surgical procedures. The patch of the present invention also may be used for isolating, occluding and/or treating deposits of vulnerable plaque, aneurysms and fistulas.
In accordance with one aspect of the invention, the patch may incorporate therapeutic drugs, genes or other bioactive agents that are eluted into the surrounding tissue to provide localized treatment or into an adjacent bloodstream to provide systemic treatment. Alternatively, such drugs, genes or other bioactive agents may be released into surrounding tissue or an adjacent bloodstream as the patch biodegrades. The patch of the present invention also may include one or radiopaque materials to enhance visibility and placement of the patch during deployment. The patches described herein may be delivered to a portion of the body using one or more delivery systems, which are per se known. The delivery system may comprise one or more expandable members (e.g., an expandable cage, a balloon, and the like), as described herein below.
In accordance with one aspect of the present invention, free-standing biodegradable patches are provided that function beneficially when delivered in the body. For example, the patch may provide mechanical support to tissue, such as where a patch is delivered intraluminally to the interior of a blood vessel to prevent restenosis or narrowing of the blood vessel. In other contexts, the inventive patch may be deployed in a vessel to seal and support a dissection in a vessel wall caused by balloon dilatation. In patients that have suffered an aneurysm, the inventive patch may be used to isolate and/or stabilize a weakened vessel wall.
The patches of the present invention additionally may provide a sealing or holding function. For example, a patch constructed in accordance with the present invention may be used to seal a perforation in a blood vessel or other hollow body organ, such as may arise during a percutaneous procedure. In other instances, a patch may be used to seal a vulnerable plaque, thereby allowing drugs to be delivered to the plaque to stabilize or dissipate the plaque without damaging the thin fibrous cap. In such applications, the patch also may promote endothelialization of the lesion. In still other instances, the patch may be employed to retain two tissue surfaces in apposition, for example, to secure two vessels that are joined during an anastomosis.
In accordance with another aspect of the invention, the patch of the present invention additionally aids in endothelialization (i.e., the process of tissue regrowth over a stent or other foreign body). In particular, the inventive patch will form a fibrin matrix in situ, thus providing a scaffold in and on which tissue may grow. When a patch is used to cover a lesion in the vasculature, such as a vulnerable plaque or a pre-existing stent, the endothelialization provided by the adhesive may reduce the risk of plaque rupture, neointimal hyperplasia or restenosis.
Patches constructed in accordance with the present invention also may be used to deliver one or more therapeutic agents to tissue, as mentioned above. For example, in some instances a stent may have been placed into a vessel to provide mechanical support. In these instances, a patch of the present invention may be placed within or around the stent to deliver an anti-restenosis agent, which may reduce the risk of in-stent restenosis and eliminate the need for stent-in-stent implantation. Additionally, the patch of the present invention may promote endothelialization by delivery of growth factors. In still other instances, one or more patches may be used to attach endothelial cells to the inside of the lumen to promote healing. In yet another proposed application, a patch of the present invention may be delivered, e.g., using a bronchoscope balloon, within a patient's bronchus or trachea to deliver chemotherapy or an anti-cancer drug through the patient's vasculature or tissue.
Although foregoing examples are directed toward intraluminal delivery of the inventive patch, it should be noted that patches constructed in accordance with the present invention may be delivered to any suitable portion of the anatomy. For example, one or more adhesives may be delivered to one or more hollow body organs, such as the esophagus, stomach, intestines, bronchus, trachea, urethra, ureters, the sinuses, the ears, or the heart. In embodiments configured for use in a heart, the patch may be used to treat or seal a patent foramen ovale, a paravalvular leak, the left auricular appendage, or the like. In other embodiments, the inventive patches may be used to modify the geometry of the left ventricle, and thus reduce functional mitral regurgitation.
In a preferred embodiment, the patch of the present invention comprises a mixture of, or separate layers of, a solid fibrinogen component and a solid thrombin component, configured to form a free-standing biodegradable film or article. When exposed to an aqueous environment, e.g., blood, the fibrinogen and thrombin components undergo polymerization in situ to form a solid fibrin film or article. This polymerization models the final stages of the clotting cascade to create a fibrin matrix similar to clots that form naturally in the human body. In accordance with one aspect of the present invention, a suspension of fibrinogen is formed using a non-aqueous solvent, such as ethanol. A predetermined amount of thrombin is dissolved in the non-aqueous solvent, and mixed with the fibrinogen suspension. The mixture then is poured into a mold, and the solvent evaporated, leaving a solid free-standing film or patch comprising unreacted fibrinogen and thrombin components. Because, in accordance with the present invention, the fibrinogen and thrombin are combined in a non-aqueous environment, the components do not polymerize to form fibrin until the patch is exposed to an aqueous environment, such as blood.
It is expected that commercially available fibrinogen products may be used to prepare a patch in accordance with the present invention, although commercial fibrinogen products that include excipients or stabilizers, such as sodium citrate or sodium chloride, have been observed to provide a relatively inflexible and fragile patch. On the other hand, commercially available purified human fibrinogen products prepared without any excipients have been observed to produce patches, when made as described herein below, having greater integrity and flexibility. One commercially available fibrinogen product that has been observed to provide satisfactory results in initial tests is Part No. PP001S, available from Hyphen Biomed, Neuville-sur-Oise, France, distributed in the United States by Aniara Corporation, Mason, Ohio. This “unsalted” fibrinogen product is used in the Examples described below.
It is expected that commercially available thrombin also may be used to prepare a patch in accordance with the present invention. Initial tests conducted with human thrombin, Part No. AEZ0060, available from Hyphen Biomed, Neuville-sur-Oise, France, distributed in the United States by Aniara Corporation, Mason, Ohio, have produced satisfactory results. In addition, the presence of some excipients in commercial sources of thrombin have not been observed to effect the mechanical characteristics of the patch.
Unlike previously-known fibrin coated stents such as those described in the Dinh patent, wherein fibrinogen and thrombin are reacted in vitro to form stent coatings, in the present invention the fibrinogen and thrombin are polymerized only after being delivered to the target location. When combined in a moist environment, thrombin converts fibrinogen into fibrin monomers, which are in turn polymerized to form fibers. These fibrin fibers join together into a network structure, resulting in a fibrin matrix. The patch of the present invention may include one or more additional components, such as calcium, Factor XIII and bovine aprotinin, which may affect the rates of polymerization and biodegradation. Importantly, because fibrin is a part of the body's natural clotting mechanism, the in situ formed fibrin patches of the present invention are biocompatible, non-thrombogenic, biodegradable, and have a high affinity for various biological surfaces.
As a further alternative, a patch in accordance with the present invention may comprise a layer of solid fibrinogen, preferably unsalted, as described above). Such fibrinogen- only or fibrinogen plus calcium salt patches are expected to have different mechanical properties when delivered to tissue compared to patches that contain thrombin. As explained earlier, however, the addition and amount of calcium salt may be tailored to obtain specific mechanical properties for a patch, as may be suitable for particular applications.
The patches of the present invention may be formed as a solid film or patch using any of a number of deposition techniques, and as described below, may include therapeutic agents or radio-opacifiers. The fibrinogen and, if present, thrombin components may be deposited on a surface via spray coating, dip coating, brushing, rolling, spinning, inkjet printing, or the like. As will be described in more detail below, a patch may be formed directly onto one or more portions of one of the delivery systems described here, such as one or more balloons. In other instances, a patch may be formed on a temporary protective layer, which may be removed before, during, or immediately prior to delivery of the patch. Preferably, the patch should have sufficient structural integrity so as to be free-standing when removed from the delivery system or temporary protective layer.
As noted above, the physical properties of a patch may change during the polymerization process, after exposure to a moist environment. Generally, as the polymerization process begins (e.g., when thrombin and fibrinogen are combined in the presence of water), the patch may temporarily become a gel and become highly adherent. Generally, it is expected that the patch may be freely manipulated, stretched, or deformed when in its temporary gel form. The duration of the gel stage may be dependent on the relative and overall concentrations of the fibrinogen and thrombin components, as well as the presence of any other components.
Both the relative and overall concentrations of each of the patch components may affect the rate of fibrin polymerization, as well as the physical characteristics of the resulting fibrin matrix. For example, a higher concentration of thrombin in a patch may shorten the setting time, thereby decreasing the amount of time the patch remains in a gel form. A higher thrombin concentration also is expected to produce a supple fibrin matrix with relatively low load-bearing capabilities. Conversely, a higher concentration of fibrinogen may increase the setting time for the patch, result in a less porous and stiffer fibrin matrix, and decrease the degradation rate of the patch. Other patch additives, such as calcium, Factor XIII, aprotinin, or other additives (e.g., plasticizers, radio-opacifiers, film-forming agents and the like) also may affect the resulting fibrin matrix. As such, the composition of the patch may be tailored to achieve a preferred setting time, matrix stiffness, porosity, and degradation rate, depending upon the intended application.
As mentioned above, the patch may include one or more additives that may affect the formation of a fibrin matrix. For example, a patch may include Factor XIII, which when activated, forms cross-links between fibrin molecule chains that stiffen the fibrin matrix. In other variations, a patch may include an inorganic calcium salt such as calcium chloride. Because calcium ions serve as a cofactor in the conversion of fibrinogen to fibrin, the presence of these calcium salts may increase the rate of polymerization. Additionally, because calcium ions are required tor the activation of Factor XIII, their presence may affect the extent of cross- linking in the fibrin matrix.
A patch constructed in accordance with the principles of the present invention may comprise one or more plasticizers that may increase the flexibility of the patch, improving the patch integrity and making it less prone to cracking or flaking. Examples of suitable plasticizers include, but are not limited to, phthalate esters (e.g., diethyl phthalate), sebacate esters (e.g., dibutyl sebacate), citrate esters (e.g., triethyl citrate, tributyl citrate), glycerol derivatives (e.g., propylene glycol, poly(ethylene glycol)), surfactants, preservatives, combinations thereof: and the like. The amount of plasticizer may vary depending on the intended application as well as the desired flexibility for the patch, and generally will comprise less than about 50% of the constituents used to prepare the patch.
In other embodiments, a patch may comprise one or more radio-opacifier substances that allow the patch to be imaged fluoroscopically prior to, during, or after implantation. Examples of suitable radio-opacifiers include, but are not limited to, materials containing bismuth, barium (e.g., barium sulphate), gold, iodine, platinum, or tantalum, zirconium oxide and iron oxide. The radio-opacifier may be provided in high concentrations in only discrete areas of the patch.
The patch of the present invention optionally may incorporate one or more film-forming agents. Generally, a film-forming agent may assist in forming a continuous film during the deposition process, and may include one or more biodegradable polymers, such as, for example, polycarboxylic acid, polyanhydrides (e.g., maleic anhydride polymers), polyorthoesters, poly-amino acids, poly(carbonate), polyethylene oxide, poly(glutarunic acid), polyphosphazenes, polylactic acid, polyglycolic acid, poly(L-lactic acid), poly(D,L,-lactide), poly (lactide acid-co-glycolic acid), 50/50 (DL-lactide-co-glycolide), polydioxanone, polypropylene fumarate, polydepsipeptides, polycaprolactone, (D,L, -lactide-co-caprolactone), poly-caprolactone co-butlacrylate, polyhydroxybutyrate valerate, polycarbonates (e.g., tyrosine-derived polycarbonates and arylates), polyiminocarbonates, cyanoacrylate, calcium phosphates, poluglycosaminogycans, polysaccharides (e.g., hyaluronic acid, cellulose, and hydroxypropylmethyl cellulose), gelatin, starches, dextrans, alginates, proteins, polypeptides, surface erodible polymers (e.g., polyhydroxybutyrate, polycaorolactone, polyanhydrides (both crystalline and amorphous), maleic anhydride copolymers, and zinc-calcium phosphate), copolymers thereof derivatives thereof, mixtures thereof, and the like.
In accordance with another aspect of the present invention, the patch optionally may incorporate one or more therapeutic agents intended for local or systemic delivery. When a patch is delivered into the body, the therapeutic agent may be at least temporarily stored in the patch. In some variations, the therapeutic agent may diffuse out of the patch. In other variations where the patch is biodegradable, the therapeutic agent may be released from the patch as the patch biodegrades. The selection of therapeutic agent or agents, the timing of delivery, and the overall amount of therapeutic agent released from the patch may be determined by the intended treatment plan, and a specific composition for the patch may be chosen to achieve this release profile. In variations where the patch includes one or more additional components (e.g., a plasticizer, a film-forming agent, etc.), any of the additional components may incorporate one or more therapeutic agents.
Examples of suitable therapeutic agents include, but are not limited to anti-inflammatory agents, anti-allergenic agents, anti-bacterial agents, anti-viral agents, anticholinergic agents, antihistamines, antithrombotic agents, anti-scarring agents, antiproliferative agents, antihypertensive agents, anti-restenosis agents, healing promoting agents, vitamins, biological molecules such as proteins, genes, growth factors, cells and DNA, combinations thereof, and the like.
Examples of suitable anti-allergenic agents that may be suitable for use with the described methods and devices include, but are not limited to, pemirolast potassium (ALAMAST®, Santen, Inc.) and any prodrugs, metabolites, analogs, homologues, congeners, derivatives, salts and combinations thereof. Examples of antiproliferative agents include, but are not limited to, actinomycin D, actinomycin IV, actinomycin 11, actinomycin XI, actinomycin C1, and dactinomycin (COSMEGEN®, Merck & Co., Inc.). Examples of healing promoting agents include, but are not limited to, sirolimus, everolimus, temsiolimus, and vitamin A.
Examples of antiproliferative agents that may be suitable for use with the described methods and devices include, but are not limited to, angiopeptin, angiotensin converting enzyme inhibitors such as captopril (CAPOTEN® and CAPOZIDE®, Bristol-Myers Squibb Co.), cilazapril or lisinopril (PRINIVIL® and PRINZIDE®, Merck & Co., Inc.); calcium channel blockers such as nifedipine; colchicines; fibroblast growth factor (FGF) antagonists, fish oil (omega 3-fatty acid); histamine antagonists; lovastatin (MEVACOR®, Merck & Co., Inc.); monoclonal antibodies including, but not limited to, antibodies specific for Platelet-Derived Growth Factor (PDGF) receptors; nitroprusside; phosphodiesterase inhibitors; prostaglandin inhibitors; suramin; serotonin blockers; steroids; thioprotease inhibitors; PDGF antagonists including, but not limited to, triazolopyrimidine; and nitric oxide, and any prodrugs, metabolites, analogs, homologues, congeners, derivatives, salts and combinations thereof.
Examples of anti-bacterial agents that may be suitable for use with the described methods and devices include, but are not limited to, aminoglycosides, amphenicols, ansamycins, β-lactams such as penicillins, lincosamides, macrolides, nitrofurans, quinoloncs, sulfonamides, sulfones, tetracyclines, vancomycin, and any derivatives or combinations thereof. Examples of penicillins that may be suitable for use with the described methods and devices include, but are not limited to, amdinocillin, amdinocillin pivoxil, amoxicillin, ampicillin, apalcillin, aspoxicillin, azidocillin, azlocillin, bacampicillin, benzylpenicillinic acid, benzylpenicillin sodium, carbenicillin, carindacillin, clometocillin, cloxacillin, cyclacillin, dicloxacillin, epicillin, fenbenicillin, floxacillin, hetacillin, lenampicillin, metampicillin, methicillin sodium, mezlocillin, nafcillin sodium, oxacillin, penamecillin, penethamate hydriodide, penicillin G benethamine, penicillin G benzathine, penicillin G benzhydrylamine, penicillin G calcium, penicillin G hydrabamine, penicillin G potassium, penicillin G procaine, penicillin N, penicillin 0, penicillin V, penicillin V benzathine, penicillin V hydrabamine, penimepicycline, phenethicillin potassium, piperacillin, pivampicillin, propicillin, quinacillin, sulbenicillin, sultamicillin, talampicillin, temocillin, and ticarcillin.
Examples of anti-viral agents suitable for use with the described methods and devices include, but are not limited to, acyclovir, famciclovir, valacyclovir, edoxudine, ganciclovir, foscamet, cidovir (vistide), vitrasert, formivirsen, HPMPA (9-(3-hydroxy-2phosphonomethoxypropyl) adenine), PMEA (9-(2-phosphonomethoxycthyl)adenine), HPMPG (9(3-Hydroxy-2-(Phosphonomet-hoxy)propyl)guanine), PMEG (9-[2-(phosphonomethoxy)ethyl]guanine), HPMPC (1-(2-phosphonomethoxy-3-hydroxypropyl)cytosine), ribavirin, EICAR (5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamine), pyrazofurin (3-[beta-D-ribofuranosyl]-4-hydroxypyrazole-5-carboxamine), 3-Deazaguanine, GR92938X (1-beta-D-ribofuranosylpyrazole-3,4-dicarboxami-de), LY253963 (1,3,4-thiadiazol-2-ylcyanamide), RD3-0028 (1,4-dihydro-2,3-Benzodithiin), CL387626 (4,4′-bis[4,6-d] [3-aminophenylN-,N-bis(2-carbamoylethyl)-sulfonilimino]-1,3,5-triazin-2-ylamino-biphenyl-2-,2′-disulfonic acid disodium salt), BABIM (Bis(5-Amidino-2-benzimidazoly-1]-methane), NIH351, and combinations thereof.
Anti-inflammatory agents may include steroidal and nonsteroidal anti-inflammatory agents. Examples of suitable steroidal anti-inflammatory agents include, but are not limited to, 21acetoxypregnenolone, alclometasone, algestone, amcinonide, beclomethasone, betamethasone, budesonide, chloroprednisone, clobetasol, clobetasone, clocortolone, cloprednol, corticosterone, cortisone, cortivazol, deflazacort, desonide, desoximetasone, dexamethasone, diflorasone, diflucortolone, difluprednate, enoxolone, fluazacort, flucloronide, flumethasone, flunisolide, fluocinolone acetonide, fluocinonide, fluocortin butyl, fluocortolone, fluorometholone, fluperolone acetate, fluprednidene acetate, fluprednisolone, flurandrenolide, fluticasone propionate, formocortal, halcinonide, halobetasol propionate, halometasone, halopredone acetate, hydrocortamate, hydrocortisone, loteprednol etabonate, mazipredone, medrysone, meprednisone, methylprednisolone, mometasone furoate, paramethasone, prednicarbate, prednisolone, prednisolone 25-diethylamino-acetate, prednisolone sodium phosphate, prednisone, prednival, prednylidene, rimexolone, tixocortol, triamcinolone, triamcinolone acetonide, triamcinolone benetonide, triamcinolone hexacetonide, any of their derivatives, and combinations thereof.
Examples of suitable nonsteroidal anti-inflammatory agents include, but are not limited to, COX inhibitors. These COX inhibitors may include COX-1 or COX nonspecific inhibitors such as, for example, salicylic acid derivatives, aspirin, sodium salicylate, choline magnesium trisalicylate, salsalate, diflunisal, sulfasalazine and olsalazine; para-aminophenol derivatives such as acetaminophen; indole and indene acetic acids such as indomethacin and sulindac; heteroaryl acetic acids such as tolmetin, dicofenac and ketorolac; arylpropionic acids such as ibuprofen, naproxen, flurbiprofen, ketoproten, fenoprofen and oxaprozin; anthranilic acids (fenamates) such as mefenamic acid and meloxicam; enolic acids such as the oxicams (piroxicam, meloxicam) and alkanones such as nabumetone. The COX inhibitors may also include selective COX-2inhibitors such as for example, diaryl-substituted furanones such as rofecoxib; diaryl-substituted pyrazoles such as celecoxib; indole acetic acids such as etodolac and sulfonanilides such as nimesulide).
Examples of suitable biomolecules include, but are not limited to, peptides, polypeptides and proteins; oligonucleotides; nucleic acids such as double or single standard DNA (including naked and eDNA), RNA, antisense nucleic acids such as antisense DNA and RNA, small interfering RNA (siRNA), and ribozymes, genes, carbohydrates. Nucleic acids may be incorporated into one or more vectors (including viral vectors), plasmids, liposomes, or the like.
Examples of suitable proteins include, but are not limited to serca-2 protein, monocyte chemoattractant proteins (“MCP-1”) and bone morphogenic proteins (“BMPs”), such as, for example. BMP-2 (OP-1), BMP-3, BMP-4, BMP-5, BMP-6 (Vgr-1), BMP-7 (OP-1), BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15. These BMPs may be provided as homodimers, heterodimers, or combinations thereof. In some variations, molecules capable of inducing an upstream or downstream effect of a BMP may be provided. This may include, for example, one or more “hedgehog” proteins, or the DNA encoding them. Examples of suitable genes include, but are not limited to survival genes that protect against cell death (e.g., anti-apoptotic Bcl-2 family factors and Akt kinase); SERCA 2 gene; and combinations thereof. In some variations, one or more therapeutic agents may comprise one or more angiogenic factors, such as acidic and basic fibroblast growth factors, vascular endothelial growth factor, epidermal growth factor, vascular endothelial growth factor, epidermal growth factor, transforming growth factor and, platelet-derived endothelial growth factor, platelet-derived growth factor, tumor necrosis factor, hepatocyte growth factor, and insulin like growth factor. In some variations, a therapeutic agent may comprise one or more cell cycle inhibitors (e.g., a cathepsin D (CD) inhibitor). Examples of suitable anti-restenosis agents include, but are not limited to, Rb, nFkB and E2F decoys, thymidine kinase (“TK”), combinations thereof and the like.
Examples of suitable small molecules include, but are not limited to, hormones, nucleotides, amino acids, sugars, and lipids and compounds have a molecular weight of less than 100 kD. Examples of suitable cells include, but are not limited to, stem cells, progenitor cells, endothelial cells, adult cardiomyocytes, smooth muscle cells, side population (SP) cells, lineage negative (Lin−) cells (e.g., Lin−CD 34-, Lin−CD34+, Lin−cKit+, and the like), mesenchymal stem cells including mesenchymal stem cells with 5-aza, cord blood cells, cardiac or other tissue derived stem cells, whole bone marrow, bone marrow mononuclear cells, whole bone marrow, bone marrow mononuclear cells, endothelial progenitor cells, skeletal myoblasts or satellite cells, muscle derived cells, go cells, endothelial cells, adult cardiomyocytes, fibroblasts, smooth muscle cells, adult cardiac fibro blasts +5-aza, genetically modified cells, tissue engineered grafts, MyoD scar fibroblasts, pacing cells, embryonic stem cell clones, embryonic stem cells, fatal or neonatal cells, immunologically masked cells and teratoma derived cells. Cells may be of human origin (autologous or allogenic), of animal origin (xenogenic), or may be genetically engineered. Any of the foregoing drugs or biologically active molecules may be encapsulated, for example, in microparticles or liposomes, prior to incorporation within the patch.
Other bioactive agents useful in the present invention include, but are not limited to, free radical scavengers; nitric oxide donors; rapamycin; methyl rapamycin; everolimus; tacrolimus; 40-O-(3-hydroxy)propyl-rapamycin; 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin; tetrazole containing rapamycin analogs; estradiol; clobetasol; idoxifen; tazarotene; alpha-interferon; host cells including, but not limited to prokaryotes and eukaryotes such as, for example, epithelial cells and genetically engineered epithelial cells; dexamethasone; and, any prodrugs, metabolites, analogs, homologues, congeners, derivatives, salts and combinations thereof.
Patches constructed in accordance with the principles of the present invention may be manufactured in either an adherent or non-adherent state. Alternatively, a patch may be manufactured in a non-adherent state, and activated prior to use, for example, by dipping in warm water prior to application or delivery to the body. As yet another alternative, the patch may include a water-soluble protective coating, for example, for intravascular applications, to prevent the fibrin polymerization process from beginning before the patch is delivered to a target location.
Referring now to
A protective layer may be removed from the patch prior to or during delivery of the patch. In this way, a patch may be configured such that only the fibrin- forming layers (as well as an additives or therapeutic agents) are delivered to tissue. The protective layer may be made from a water-soluble material, a material that is soluble in another media, a material that is electrolytically decomposable, a bioerodable or biodegradable material, combinations thereof, or the like. Examples of suitable water-soluble materials include, but are not limited to, polysaccharides (e.g., hyaluronic acid, cellulose, hydroxypropylmethyl cellulose, gelatin, starches, dextrans, alginates, their derivatives, and the like), contrast agents (e.g., diatrizoate, metrizoate, ioxaglate, iopamidol, iohexol, ioxilan, iopromide, iodixanol, and the like), sugar- based polymers (e.g., sucrose), water-soluble hydrogels, combinations thereof, and the like.
In
Referring to
When patch 400 is delivered, e.g., through the vasculature of a patient, the solid unreacted fibrinogen and thrombin portions 402 may adhere to tissue. However, matrix 404, which may be a water-soluble material, initially protects the fibrin-forming components from polymerizing. As water-soluble matrix 404 dissolves during exposure within the body, portions 402 are exposed, thereby initiating polymerization. Such exposure also may allow the fibrin gel to adhere to the bodily tissue and cure to form a fibrin-matrix patch. Pressure applied by a delivery device (e.g., by an inflated balloon), may cause portions 402 to join and form a continuous film within the body. In other embodiments, matrix 404 may be a biodegradable material, such that exposed portions of the unreacted fibrin-forming components 402 become adherent, thereby allowing patch 400, including biodegradable matrix 404, to adhere to surrounding tissue.
In other variations, a patch of the present invention may be formed with the unreacted fibrinogen and thrombin components, or just a fibrinogen component, arranged in predetermined patterns. For example, in some variations, the fibrin-forming components may be arranged in a mesh-like pattern. In still other variations, the fibrin-forming components may be divided into a plurality of discrete segments.
As illustrated in
Dividing the unreacted fibrinogen and thrombin components into discrete segments 504 may provide a number of advantages. For example, a patch made up of discrete segments 504 may have additional flexibility compared to a solid continuous layer, thereby enabling the patch to be folded to facilitate transluminal delivery. In other instances, discrete segments 504 may be used to form a continuous patch that will not block a side branch when deployed in a branched blood vessel. In such cases, it is expected that only those segments 504 that contact a tissue surface will deform, and thus segments 504 that do not contact tissue will not contribute to forming a continuous film. As such, if a balloon carrying discrete segments 504 is expanded inside of a branched vessel, those segments that are expanded toward the side branch will not contact tissue, and thus will not become part of the resulting patch.
A patch of the present invention may have any suitable size and shape, such that the dimensions of the patch may be determined at least in part by the dimensions of the anatomy in which the patch will be applied. In addition, solid patches of unreacted fibrinogen or thrombin, with or without additional additives as described above, may be modeled into any suitable size of shape, depending upon the intended application.
Other suitable three dimensional shapes may include, but are not limited to, spheres, hemispheres and cones. In
In other embodiments, a patch constructed in accordance with the principles of the present invention may be formed in a flat shape, such as patch 612 of
It should be appreciated that the shape and dimensions of a patch may change before or during delivery of the patch. For example, the patch may be folded, crimped, stretched or otherwise deformed in a manner that modifies, temporarily or permanently, the shape of the patch. Furthermore, the ultimate size and shape of the in situ patch formed within the body may differ from the shape of the patch as manufactured. Due to the deformability of the fibrinogen and thrombin components during polymerization, some patches may be molded or otherwise deformed during delivery. For example, in variations where a cylindrical patch is delivered using a balloon, inflation of the balloon may cause the patch to expand to a larger radius.
The patches described herein may be delivered using of a number of previously-known delivery systems, which may comprise one or more expandable members, such as a balloon or expanding mandrel or cage. In embodiments that include an expandable member, the expandable member may be expanded at the delivery site to position a patch so that it is in apposition with tissue. In instances where a patch is placed in a dry environment, or when the delivery system is used to deliver a liquid component, the delivery system may additionally include one or more lines, lumens, ports or the like for delivering water or a liquid component to activate the patch.
In instances where the patch is delivered using a balloon catheter, the balloon may be compliant, semi-compliant, or non-compliant. Non-compliant balloons are relatively inelastic, and the balloon material does not stretch significantly when the balloon is inflated. As such, a deflated non-compliant balloon usually will have excess material that is folded or rolled to place the balloon in a low-profile configuration. Conversely, compliant balloons are relatively elastic, and thus the material tends to stretch and expand when the balloon is inflated. A deflated non-compliant balloon may not have an excess of balloon material, and thus may not need to be folded or rolled. Semi-compliant balloons tend to have an intermediate level of elasticity and upon inflation stretch and expand to a lesser degree than compliant balloons would under similar circumstances. Semi-compliant balloons may or may not need to be rolled or folded.
When a balloon catheter is used to deliver a patch of the present invention, the patch may first be placed on or otherwise attached to the balloon. In some variations, a patch may be mechanically attached to the balloon. Alternatively, one or more clips, sutures, coatings or other mechanical structures may be used to hold the patch to the balloon. In variations where a non- or semi-compliant balloon is either folded or rolled, the folding or rolling of the balloon may hold the patch against or to the balloon.
In other embodiments, the patch may be temporarily attached to the balloon using one or more adhesives, which may be water-soluble and release the patch when exposed to water. For example, in some variations a water-soluble protective layer may be used to join a patch to a delivery system and later release the patch from the delivery system. In other variations, the adhesive may lose its grip on the balloon in response to one or more stimuli (e.g., heat, energy, electricity) which may be applied to the balloon catheter to release the patch in situ.
In still other embodiments, the unreacted fibrinogen and/or thrombin components of the patch may be deposited directly onto the balloon of a delivery catheter using any suitable deposition process. Examples of suitable deposition methods include, but are not limited to, spray coating, dip coating, brushing, rolling, spinning, inkjet printing, casting or the like. Where the patch comprises multiple layers (e.g., protective layers and adhesive layers), each layer may be applied sequentially, and may be applied using the same or different deposition methods. For example, a balloon may first be coated with a protective layer, a layer of unreacted fibrinogen and thrombin then applied, and finally the assembly may be coated with an additional protective layer, such as a water-soluble layer. When multiple discrete segments are used to create the patch, such as described with respect to patch 500 of
When the fibrin-forming components are used to at least partially coat a balloon, the balloon may be either deflated or inflated when coated. For example, in some variations an inflated non-compliant or semicompliant balloon may be coated with a patch, deflated, and then rolled or folded with the solid patch attached thereto. In other instances, a deflated non-compliant or semicompliant balloon may be rolled or folded, and then coated with a patch. Compliant balloons may be coated when they are at least partially deflated. Additionally, the balloon of a balloon catheter may be made from or coated with a non-stick material, such as PTFE. In this case, the non-stick material may help to prevent the patch from adhering to the balloon during patch activation and delivery. The balloon of the delivery catheter optionally may be textured, dimpled, or otherwise patterned to allow for temporary mechanical adherence between the balloon and the patch.
Referring now to
Delivery systems suitable for delivering the patch of the present invention may additionally comprise one or more protective sheaths. Generally, an expandable member may be placed in a low-profile configuration inside of a sheath, and advanced to a target site. At the target site, the sheath may be withdrawn (or the expandable member advanced) to reveal the expandable member. In this way, the sheath may help to shield the patch from exposure to moisture or other stimuli as the patch is advanced through the body. One such delivery system is depicted in
In
In accordance with another aspect of the present invention, methods are provided for delivering one or more fibrin-matrix forming patches to a body. The patches may be delivered to any suitable portion of the anatomy, including the interior of a blood vessel, and may provide localized or systemic delivery of one or more biological molecules or therapeutic agents. In some applications, the patches may be used to seal a puncture, tear, or dissection in a blood vessel. In other applications, the patches may be used to support a vessel, such as a vessel weakened by aneurysm, or to occlude or isolate an aneurysm or fistula. In still other applications, one or more patches may be used to support or reline a stent disposed within a blood vessel or to support or seal a vulnerable plaque. The patches of the present invention also may be delivered to the heart, for example, to close a patent foramen ovale, a paravalvular leak, the left auricular appendage, or to modify the geometry of the left ventricle.
As described above, the patch of the present invention may be delivered using any suitable delivery system, such as those described above. The delivery system may comprise a sheath, which may or may not be steerable. Advancement of the delivery system and deployment of the patch may occur under direct visualization, indirect visualization, or a combination thereof. In variations where the delivery system is advanced using indirect visualization, any suitable visualization technique may be used (i.e., fluoroscopy, ultrasound), and either the delivery system or the adhesive may include one or more radiographic components to help aid in visualization.
Once the patch has been advanced to the target location, it may be positioned such that it is in contact with bodily tissues. The delivery system preferably places the patch in contact with bodily tissue such as by expanding an expandable member (e.g. a balloon). In some instances, the expansion of a balloon or other expandable member causes the patch to stretch or deform when in a gel state. The delivery system may continue to hold the patch in contact with the bodily tissue in a stretched or deformed state until the fibrin matrix cures, so as to not diminish the strength of the patch during curing.
The patch may be manufactured in a non-adherent form, and activated at any time prior to or during delivery. Generally, this occurs when the patch is exposed to a moist environment. In some applications, a user may activate a patch prior to introducing the patch into the body. Assuming the setting time for the patch is known, a user may monitor the time remaining before the in situ patch sets. Such embodiments may additionally benefit from a patch composition having a longer setting time (e.g., greater than five minutes), thereby enabling the patch to be advanced to and placed at a target location.
As discussed above, activation of the unreacted fibrinogen and thrombin components may be controlled by the presence of one or more protective layers. In these embodiments, one or more protective layers may protect the patch from activating substances or stimuli. Once the protective layers are removed or dissolve, the fibrin-forming components begin polymerizing. For example, in variations where the patch is covered by a water-soluble protective layer or is impregnated in a water-soluble matrix, the layer or matrix may be configured to dissolve over a predefined period of time when introduced into an aqueous environment. In this way, fibrin polymerization will begin a predetermined interval after introduction into an aqueous environment. In other applications, a user may initiate polymerization by selective removal of a protective layer or applying an activating substance to the patch.
In yet other methods, as described above, the delivery system may control adhesive activation. For example, the patch may be delivered via one or more sealed sheaths, such that activation may be selectively initiated by unsealing the sheath and allowing the patch to be exposed to one or more activating substances or stimuli in the surrounding environment. In other embodiments, the delivery system may be configured to introduce a liquid component to activate the patch prior to deployment, e.g., by flushing a fluid through the interior of the sealed sheath to activate the patch prior to deploying the patch from the sheath.
In embodiments where a delivery system is used to introduce the inventive patch to a target location, the delivery system may be removed at any suitable time. In some applications, the delivery system may be removed once the patch has been placed in contact with bodily tissue, but before it has fully set. In other applications, the delivery system may be retained in position until the patch has fully set. Placement of patch may be confirmed via direct or indirect visualization prior to removal of the delivery device.
The patches described herein may be micronized into small pieces or fine powders before delivery to a patient, where the patches are reconstituted in situ. The small pieces may assume a particular shape for the convenience of delivery, such as but not limited to rods, discs, or pellets of irregular shapes. The patches may be constructed as described above, and then micronized into pieces or powders having a suitable size profile for delivery to a target site of a patient. Depending on the practical needs, the micronized patch may be delivered to the nasal cavity, including sinuses, and/or other tissues or surfaces of a patient.
Various applicators may be used to deliver micronized patches of the present invention to a target site of a patient. Such applicators include but are not limited to conventional powder inhalation or spraying devices, such as dry powder inhalers (DPIs), dry powder nebulizers, metered-dose inhalers, pressurized dose sprayers, and airbrush, etc. Alternatively, the applicator may comprise a balloon catheter system.
Referring now to
Referring now to
Patients may self-administer micronized patches, e.g., powders, by spraying or inhaling the powders into their nostrils. Alternatively, a physician may apply the micronized patches to a pathogenic site before, during, or after a surgical procedure.
The micronized patches, e.g., powders or small pieces, as manufactured preferably are non-adhesive prior to administration to a patient, and become adhesive once delivered at a target site. Adhesive activation may be controlled by the presence of one or more protective barriers that prevent the micronized patch from being exposed to one or more activating stimuli. For example, the micronized patch may be sealed in a dry environment before administration, and become adhesive when exposed to moisture, such as within a patient's nasal cavity. As discussed above, adhesive activation may also be controlled by the delivery tool.
Upon the micronized patch becoming adhesive and sticking to nearby tissues, the formulations may slowly release a therapeutic agent over time. This feature of prolonged release may reduce the frequency at which a pharmaceutical composition containing the micronized patch needs to be administered to a patient, as compared to a pharmaceutical composition without the micronized patch. The time period of effective release may range from a few hours to days, weeks, or months.
According to one aspect of the present invention, provided herein are methods and related pharmaceutical dosage forms, and kits for preventing or treating a nasal condition in a subject. The present method involves treatment of a nasal condition by delivering a pharmaceutical dosage form to a local pathogenic site within the subject's nasal cavity and/or nearby tissues. The pharmaceutical dosage form comprises patches constructed in accordance with the principles of the present invention, and optionally at least one therapeutic agent effective for treating the nasal condition. The patches, containing one or more therapeutic agents, are capable of releasing them after delivery, and preferably in a controlled fashion. The kit comprises the pharmaceutical dosage form, and applicators for the delivery and deployment of the dosage form into a target site.
As used herein, a subject refers to an animal that is the object of treatment, observation or experiment. Animal includes cold- and warm-blooded vertebrates and invertebrates such as fish, shellfish, reptiles and, in particular, mammals. Mammal includes, without limitation, mice; rats; rabbits; guinea pigs; dogs; cats; sheep; goats; cows; horses; primates, such as monkeys, chimpanzees, apes, and prenatal, pediatric, and humans.
As used herein, “preventing” means preventing in whole or in part, or ameliorating or controlling. As used herein, the term “treating” refers to both therapeutic treatment and prophylactic or preventative measures, or administering an agent suspected of having therapeutic potential.
As used herein, “nasal cavity” broadly refers to any cavity and passageway that is present in the anatomical structures of the nasal region including the nasal passageway, the frontal sinuses, the maxillary sinuses, the sphenoid sinuses, and the ethomoid sinuses (collectively the “paranasal sinuses”).
As used herein, “nearby tissues” of the nasal cavity include bodily tissues and structures located inside or around the nasal cavities, including but not limited to, tissues surrounding the nasal passageway, and paranasal sinuses, eye tissues, tear duct, Eustachian tubes, and the adenoids, and may be hard tissue or soft tissue, including but not limited to, bone, cartilage, muscle, fat, fibrous tissue, blood vessels, nerves, and mucosa.
The present method involves treatment of a nasal or sinus condition by delivering a pharmaceutical dosage form to a local pathogenic site within the subject's nasal cavity and/or nearby tissues. A nasal condition may be any condition where therapeutic, prophylactic and/or preventative measures may be taken by delivering a therapeutic agent to a subject's nasal cavities or nearby tissues. A local pathogenic site may be a tissue with a nasal or sinus condition to be treated, for example, inflamed or wounded tissue, or polyps. Alternatively, a local pathogenic site may be a tissue for absorbing the therapeutic agent either locally or for systemic circulation.
Nasal conditions treatable with the present invention may include, but are not limited to, diseases or symptoms caused by the presence of one or more pathogenic sites within the subject's nasal cavities or tissues, such as in the subject's nostrils, nares or nasal chambers, limen, vestibule, greater alar cartilage, alar fibrofatty tissue, lateral nasal cartilage, agger nasi, floor of the nasal cavity, turbinates, and cavities and tissues in the paranasal sinuses (e.g., frontal sinuses, ethmoid sinuses, sphenoid sinuses, and maxillary sinuses, ethmoidotomy channel, frontal sinus outflow tract, osteomeatal complex, maxillary ostium, etc.), and nasal septum. The pathogenic sites may be located in the soft tissues, cartilages, bones and/or blood vessels in the nose and paranasal sinuses.
The nasal conditions or symptoms may be acute, sub-acute, recurrent, or chronic. Exemplary nasal conditions and symptoms treatable with the present invention include, but are not limited to, infections in the nasal tissues or cavities, allergic reactions in the nasal tissues or cavities, inflammations in the nasal tissues or cavities, physical injury or wounds to nasal tissues or cavities, or any combination thereof. Exemplary conditions include, for example, bacterial or viral nasal infections, nasal vestibulitis, infectious rhinitis, acute viral rhinitis, atrophic rhinitis, allergic rhinitis, acute rhinitis, chronic rhinitis, vasomotor rhinitis, infections sinusitis, maxillary sinusitis, frontal sinusitis, ethmoid sinusitis, sphenoid sinusitis, acute sinusitis, chronic sinusitis, subacute sinusitis, recurrent sinusitis, nasal polyps, chronic rhinosinusitis with nasal polyps (CRSwNP), obstruction, congestion, stenosis, adhesions in the nasal or sinus passageways, wounds, post-operational lesions, nosebleeds, septum perforations, etc.
For treating a nasal condition with the present method, a patch constructed according to the principle of the present invention may be delivered and applied in the vicinity of a pathogenic site within or near the subject's nasal cavity. The delivery location is preferably near, adjacent to, or directly on top of a pathogenic site, including locations within the patient's nasal cavities, including sinuses. Such pathogenic sites include, but are not limited to, an infected tissue, a swollen and inflammatory tissue, a topical lesion, a fibrous tissue, a bleeding site, polyp-concentrated area, a congested or obstructed area in the nasal cavities, etc.
Certain target pathogenic sites may be reached trans-nasally, i.e., through a nostril without the need for surgically opening or exposing the nasal cavity or tissue, such that the procedure for delivering and disposing the patch at the pathogenic site does not require surgically opening or exposing the nasal cavity or tissue. In one exemplary application, an applicator having at least a portion of suitable shape and dimension may be advanced through the nostril and finer passages of the nasal cavity to access a target pathogenic site. The applicator may carry a pathogenic dosage form, such as a patch constructed according to the principle of the present invention, and apply or deploy the pathogenic dosage form at the target site. Movement and action of the applicator inside the nasal cavity may be controlled by a medical practitioner or by a controlling apparatus. The applicator may be a stand-alone device, or a component of a system or apparatus. Additional devices, systems, and methods for the delivery of pharmaceutical dosage forms, such as a patch constructed according to the principle of the present invention are described in U.S. Provisional Application No. 62/447829 titled “Devices, Systems, and Methods for Delivering Therapeutic Substances in a Mammalian Body,” the entirety of which is incorporated herein by reference.
In proposed applications, the applicator may be used to carry and deploy a patch to areas such as, but not limited to, a paranasal sinus, e.g., frontal sinuses, sphenoid sinuses, ethomoid sinuses, and maxillary sinuses, an ethmoidotomy channel, and a frontal sinus outflow tract. A patch may also be delivered using a delivery system to the osteomeatal complex along the maxillary ostium, or any sinus insertion device capable of accessing the maxillary ostium.
The present pharmaceutical dosage form may be delivered to a target pathogenic site during a nasal surgery, such as a surgery for treating rhinitis, sinusitis and/or polyps. For example, one or more patches according to the present invention may be placed on or near diseased tissues exposed during surgery, before the surgical openings are closed for healing. The nasal surgery may be minimally invasive; the procedure may be performed through tiny incisions instead of one large opening on the subject's bodily tissue. The applicator described herein may be used to pass through one of more of the incisions for delivering the pharmaceutical dosage form.
The pharmaceutical dosage form in accordance with the principles of the present invention may be delivered to the nasal cavity for treating conditions that are otherwise treated with medications in the formulation of nasal sprays. When the patch is deployed in the target pathogenic site, it adheres to the target pathogenic site and releases the therapeutic agent in a sustained fashion. The therapeutic agent may act on the local mucosal tissue to treat conditions, for example, inflammatory diseases of the sinuses. Alternatively, the therapeutic agent may be absorbed to the systemic circulation, the central nervous system, or the eye. In one non-limiting example, such delivery is achieved by applying the patch in the nasal cavity near intranasal blood vessels for systemic circulation. In another example, the patch may be applied on a portion of the nasal epithelium in close anatomical proximity to at least one intranasal nerve structure (InNS) for absorption by the central nervous system.
In such nasal, sinus, and other applications, the pharmaceutical dosage form is purported to induce and/or enhance an intended therapeutic effect in treating the nasal condition. In a proposed application, a patch constructed in accordance to the present invention may exert the desired therapeutic effect.
In a related proposed application, the patch may further incorporate one or more other therapeutic agents intended for local or systemic delivery. In variations where the patch includes one or more films, each of the films may incorporate one or more therapeutic agents. These therapeutic agents may be any pharmaceutically acceptable substance that demonstrates a beneficial effect for the subject's nasal condition. The beneficial effect may include restoring or maintaining health in the nose or nearby organs, alleviating one or more symptoms, and/or delaying or preventing progression or onset of a disease. The therapeutic agent may be in the form of a chemical drug, a biologics, or a prodrug. In the context of a particular nasal condition, a therapeutic agent may prevent or inhibit one or more signs or symptoms or laboratory findings associated with that nasal condition to be treated. The films of a patch in accordance with the principals of the present invention may comprise the same therapeutic agent, different therapeutic agent, or the same therapeutic agent with different concentration or release profile.
A patch constructed according to the principles of the present invention comprises one or more corticosteroids as a therapeutic agent for treating a nasal condition, such as allergic rhinitis or CRSwNP. Corticosteroid is a class of steroids having anti-inflammatory effect that may include, but are not limited to, amcinonide, betamethasone benzoate, betamethasone dipropionate, betamethasone valerate, clobetasol propionate, clocortolone pivalate, desonide, desoximetasone, dexamethasone, dexamethasone sodium phosphate, diflorasone diacetate, fluocinonide, fluocinolone acetonide, flurandrenolide, fluticasone propionate, halcinonide, halobetasol propionate, hydrocortisone, hydrocortisone butyrate, hydrocortisone valerate, mometasone furoate, prednisolone acetate, triamcinolone acetonide, and combinations thereof.
As used herein, corticosteroids also include therapeutically active analog, derivative, pharmaceutically acceptable salt, prodrug, metabolite or conjugate thereof. As used herein, a derivative includes a therapeutically active or pharmaceutically active fragment of a compound modulating the activity of a mineralocorticoid receptor or a glucocorticoid receptor. An analog may be a structural analog or a functional analog. A homolog comprises a molecule of the same chemical type, but differing by a fixed increment of an atom or a constant group of atoms.
In other embodiments, a patch constructed according to the principles of the present invention comprises one or more antihistamine as a therapeutic agent for treating a nasal condition. Antihistamine is a class of therapeutic compounds that inhibits the action of histamine via one or more histamine receptors. Typically, an anti-histamine blocking Hi receptors is used to treat coughing, a cold, and/or an allergic reaction. Examples of suitable antihistamines include, without limitation, Acrivastine, Alimemazine, Astemizole, Azatadine, Bromodiphenhydramine, Brompheniramine, Carbinoxamine, Cetirizine, Chlorpheniramine, Clemastine, Cyproheptadine, Desloratadine, Dexchlorpheniramine, Dextrobrompheniramine, Dimenhydrinate, Diphenhydramine, Doxylamine, Fexofenadine, Hydroxyzine, Levocetirizine, Loratadine, Meclizine, Mizolastine, Quetiapine, Pheniramine, Promethazine, Pyrilamine, Tripelennamine, and Triprolidine.
In yet another embodiment, a patch constructed according to the principles of the present invention comprises one or more antibodies as a therapeutic agent for treating a nasal condition. Exemplary antibodies include, but are not limited to, omalizumab mepolizumab dupilumab, and other monoclonal antibodies that target factors associated with the type 2 inflammations in the polyp tissue.
In other embodiments, a patch constructed according to the principles of the present invention comprises one or more leukotriene receptor antagonist as a therapeutic agent for treating a nasal condition. As used herein, leukotriene receptor antagonist is a substance that itself has a function to inhibit action on leukotriene receptors. Examples thereof include BLT receptor antagonists and CysLT receptor antagonists. Among the leukotriene receptor subtypes, BLT and CysLT are coupled to Gi and Gq. BLT receptor antagonist is a substance that itself has a function to inhibit action on BLT receptors. As used herein, the term “CysLT receptor antagonist” means a substance that itself has a function to inhibit action on CysLT receptors. Examples of the BLT receptor antagonists and/or the CysLT receptor antagonists include LY 255283, zafirlukast, pranlukast, montelukast, ablukast, pobilukast edamine, ritolukast, sulukast, tipelukast, tomelukast, verlukast, and derivatives thereof, and pharmacologically acceptable salts thereof.
In yet another embodiment, a patch constructed according to the principles of the present invention may comprise one or more anti-inflammatory cytokines for treating a nasal condition. Anti-inflammatory cytokine is a cytokine that is involved in the reduction of an inflammatory reaction. Exemplary anti-inflammatory cytokines include, but are not limited to, IL-4, IL-10, IL-11, IL-13, TGFβ, IL-35, LIF, CTLA-4, CD39, galectin 1, galectin 3, galectin 9, and PD-L1.
In yet another embodiment, a patch constructed according to the principles of the present invention may comprise one or more vasoconstrictive agents for treating a nasal condition. The term “vasoconstrictive agent” appearing herein may refer to one or more agents that can constrict vessels. The vasoconstrictive agent may comprise one or more suitable vasoconstrictive drugs in any suitable formulation or combination. Examples of vasoconstrictive drugs include, but are not limited to, a vasoconstrictor, a sympathomimetic, methoxyamine hydrochloride, epinephrine, midodrine hydrochloride, desglymidodrine, and an alpha-receptor agonist, stimulant or activator.
Other suitable therapeutic agents that may be used in connection with the present invention include, but are not limited to, other anti-inflammatory agents, anti-allergenic agents, anti-bacterial agents, anti-viral agents, healing promoting agents, clotting promoting agents, vitamins, biological molecules such as proteins, genes, growth factors, cytokines, cells and DNA, combinations thereof, and the like. Suitable therapeutic agents encompass those currently known and those to be discovered in the future.
A patch according to the present invention may be configured to release the contained therapeutic agent via different modes. When a patch is delivered into the body, the therapeutic agent may be at least temporarily stored in the patch. The patch may be activated at some point to become capable of releasing the therapeutic agent, which may be locally or systematically absorbed to exert the therapeutic effect. In some variations, the therapeutic agent may diffuse out of the patch. In other variations where the patch is biodegradable, the therapeutic agent may be released from the patch as the patch biodegrades. The selection of therapeutic agent or agents, the timing of delivery, and the overall amount of therapeutic agent released from the patch may be determined by the intended treatment plan, and a specific composition for the patch may be chosen to achieve this release profile. The composition of the patch may be tailored to achieve a preferred setting time, matrix stiffness, porosity, and degradation rate, depending upon the intended application.
A patch constructed according to the principles of the present invention may be configured to release a therapeutic effective amount of a therapeutic agent, preferably in a controlled fashion. Controlled release refers to when all or less than all of the total amount of the pharmaceutical dosage form according to the present invention delivers a therapeutic agent over a prolonged period of time greater than 1 hour. During the prolonged releasing period, the releasing rate of the therapeutic agent can be substantially constant or varied.
A therapeutically effective amount or dose is that amount or dose sufficient to inhibit or prevent onset or advancement, to treat outward symptoms, or to cause regression, of a disease. The therapeutically effective amount or dose also can be considered as that amount or dose capable of relieving symptoms caused by the disease. In the context of treatment of a nasal condition, a therapeutically effective amount or dose of a therapeutic agent may be that amount or dose sufficient to achieve a stated therapeutic effect, such as clearance of a nasal infection, removal of an allergic symptom, stopping of nosebleeds, etc. The therapeutically effective amount may vary depending the subject and disease condition being treated, e.g., the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art.
A pharmaceutically effective dose of a therapeutic agent may be delivered with one or more patches constructed in accordance with the principles of the present invention. Multiple patches may be administered simultaneously or sequentially, targeting the same or different pathogenic sites. The multiple patches may also contain the same or different unit dose(s) of a particular therapeutic agent, or contain different or different groups of therapeutic agents.
The patch composition and configuration may determine the amount, rate, and duration for the release of the therapeutic agent. The term “unit dose” when used in reference to the pharmaceutical dosage form of the present invention refers to physically discrete units suitable as unitary dosage for the subject being treated, each unit containing a predetermined quantity of the therapeutic agent calculated to produce a desired therapeutic effect when delivered with a patch constructed according to the principle of the present invention. The unit doses and the timing for their administration depend on a variety of factors, such as the subject to be treated, capacity of the subject's system to utilize the therapeutic agent, and degree of therapeutic effect desired.
The unit dose of a therapeutic agent contained in a patch of the present invention may be in the range of from about 1 ng to about 1000 ng, about 20 ng to about 950 ng, about 40 ng to about 900 ng, about 75 ng to about 850 ng, about 150 ng to about 750 ng, about 200 ng to about 700 ng, about 300 ng to about 600 ng, about 400 ng to about 500 ng, and any and all whole or partial increments there between. The unit dose of a therapeutic agent contained in a patch of the present invention may be in the range of from about 1 μg to about 1000 μg, about 20 μg to about 950 μg, about 40 μg to about 900 μg, about 75 μg to about 850 μg, about 150 μg to about 750 μg, about 200 μg to about 700 μg, about 300 g to about 600 μg, about 400 μg to about 500 μg, and any and all whole or partial increments there between.
The unit dose of a therapeutic agent contained in a patch of the present invention may be in the range of from about 1 mg to about 10,000 mg, about 20 mg to about 9,500 mg, about 40 mg to about 9,000 mg, about 75 mg to about 8,500 mg, about 150 mg to about 7,500 mg, about 200 mg to about 7,000 mg, about 3050 mg to about 6,000 mg, about 500 mg to about 5,000 mg, about 750 mg to about 4,000 mg, about 1 mg to about 3,000 mg, about 10 mg to about 2,500 mg, about 20 mg to about 2,000 mg, about 25 mg to about 1,500 mg, about 50 mg to about 1,000 mg, about 75 mg to about 900 mg, about 100 mg to about 800 mg, about 250 mg to about 750 mg, about 300 mg to about 600 mg, about 400 mg to about 500 mg, and any and all whole or partial increments there between.
The unit dose of a therapeutic agent contained in a patch of the present invention may be from about 1 mg and about 2,500 mg, or less than about 10,000 mg, or less than about 8,000 mg, or less than about 6,000 mg, or less than about 5,000 mg, or less than about 3,000 mg, or less than about 2,000 mg, or less than about 1,000 mg, or less than about 500 mg, or less than about 200 mg, or less than about 50 mg. Similarly, a dose of a second compound (i.e., a drug used for treating the same or another disease as that treated by the compositions of the invention) as described herein may be less than about 1,000 mg, or less than about 800 mg, or less than about 600 mg, or less than about 500 mg, or less than about 400 mg, or less than about 300 mg, or less than about 200 mg, or less than about 100 mg, or less than about 50 mg, or less than about 40 mg, or less than about 30 mg, or less than about 25 mg, or less than about 20 mg, or less than about 15 mg, or less than about 10 mg, or less than about 5 mg, or less than about 2 mg, or less than about 1 mg, or less than about 0.5 mg, and any and all whole or partial increments thereof.
The rate of biodegradation of the patch may correlates to the releasing rate of the therapeutic agent. The releasing rate may be constant or changing. For example, the patch may be configured to release the therapeutic agent at an average rate ranging from about 1 ng per day to about 1000 μg per day. In various embodiments, the therapeutic agent may be released at 5 ng per day or less, or 10 ng per day or less, or 20 ng per day or less, or 30 ng per day or less, or 40 ng per day or less, or 50 ng per day or less, or 100 ng per day or less, or 150 ng per day or less, or 200 ng per day or less, or 250 ng per day or less, or 300 ng per day or less, or 350 ng per day or less, or 400 ng per day or less, or 450 ng per day or less, or 500 ng per day or less, or 550 ng per day or less, or 600 ng per day or less, or 650 ng per day or less, or 700 ng per day or less, or 750 ng per day or less, or 800 ng per day or less, or 850 ng per day or less, or 900 ng per day or less, or 950 ng per day or less, or 1 μg per day or less, or 1.5 μg per day or less, or 2 μg per day or less, or 2.5 μg per day or less, or 3 μg per day or less or 3.5 μg per day or less or 4 μg per day or less, or 4.5 μg per day or less, or 5 μg per day or less, or 5.5 μg per day or less, or 6 μg per day or less, or 6.5 μg per day or less, or 7 μg per day or less, or 7.5 μg per day or less, or 8 μg per day or less, or 8.5 μg per day or less, or 9 μg per day or less, 9.5 μg per day or less, 10 μg per day or less, 15 μg per day or less, 20 μg per day or less, 25 μg per day or less, 30 μg per day or less, 35 μg per day or less, 40 μg per day or less, 45 μg per day or less, 50 μg per day or less, 55 μg per day or less, 60 μg per day or less, 65 μg per day or less, 70 μg per day or less, 75 μg per day or less, 80 μg per day or less, 85 μg per day or less, 90 μg per day or less, 95 μg per day or less, 100 μg per day or less, 200 μg per day or less, 300 μg per day or less, 400 μg per day or less, 500 μg per day or less, 600 μg per day or less, 700 μg per day or less, 800 μg per day or less, 900 μg per day or less, 1000 μg per day or less, and any and all whole or partial increments there between.
The present method of treatment may be used alone or in combination with other therapies to achieve the result of treatment. For example, one or more patches containing at least one therapeutic agent may be administered to the nasal or sinus cavity before, during or after a nasal or sinus surgery, such as an ethmoidectomy or endoscopic sinus surgery (FESS). Additionally or alternatively, a patch containing a therapeutic agent may be administered simultaneously or sequentially with the administration of the same or different therapeutic agent(s) via a different administration route, such as via oral, nasal, rectal, parenteral, sublingual, transdermal, transmucosal (e.g., sublingual, lingual, (trans)buccal, (trans)urethral, vaginal (e.g., trans- and perivaginally), (intra)nasal, and (trans)rectal), intravesical, intrapulmonary, intraduodenal, intragastrical, intrathecal, subcutaneous, intramuscular, intradermal, intra-arterial, intravenous, intrabronchial, inhalation, and topical administration. Additionally or alternatively, a patch constructed according to the principle of the present invention may be administered in conjunction with other intra-nasal devices or implants.
Additionally or alternatively, the present method of treatment may be performed after at least one prior clinical therapy is deemed to have failed. Such prior clinical therapies may include, but are not limited to, oral administration of antihistamines and anti-inflammatory steroids, topical administration of antihistamines and anti-inflammatory steroids, for example via nasal sprays or drops, and nasal or sinus surgery. Additionally or alternatively, the present method of treatment may be used for local delivery of a therapeutic agent when systemic exposure to the therapeutic agent is toxic, likely to produce serious adverse or side effects, or otherwise less preferred.
A patch in accordance with the principles of the present invention was prepared using commercially available fibrinogen, thrombin and calcium chloride. It was observed that the type, amount and ratio of these components significantly affects the properties of the patch, including flexibility, microstructure, and adhesive strength. As discussed in later examples, it was found that the addition of additives rendered the patch more flexible.
Fibrinogen powder was prepared by grinding 25 mg of commercially available fibrinogen and suspending it in 1 ml of ethanol. 10 NIH of commercially available thrombin was first dissolved in 2 ml of water. 4.4 mg of CaCl2 was dissolved in 1 ml of ethanol. 160 μl of thrombin solution was added to the CaCl2 solution and mixed. The resulting mixture was added to the fibrinogen suspension, mixed, and then poured into a circular mold having a surface area of 10 cm2. The mold was placed under 30 mm Hg vacuum for three hours to evaporate the ethanol and water. A free-standing patch was formed having sufficient strength to be removed from the mold. The patch, when exposed to saline, became elastic and adhesive.
The strength of the patch in its dry state is important, as the patch must have sufficient structural integrity to be free-standing, and yet retain sufficient flexibility to be configured for delivery via a delivery system, e.g., wrapped around a balloon and tightly folded. Several parameters were observed to effect the strength and flexibility of the patch, including:
25 mg of unsalted fibrinogen was suspended in 1 ml ethanol and 100 μl of a 100 mg/ml solution of PEG-400 was added to the fibrinogen suspension. A thrombin solution containing CaCl2 was prepared as in Example 1 and mixed with the suspension of fibrinogen and PEG-400. The resulting mixture was mixed and poured into a circular mold having a surface area of 10 cm2 and then placed under 30 mm Hg vacuum for three hours to dry. The patch was measured to have a thickness of about 150 μm, and was stored in an environment with 60% humidity.
A delivery system suitable for delivering a patch as described in the preceding examples was prepared including a standard angioplasty catheter onto which a water soluble coating was applied to ensure release of the patch from the balloon. A water soluble coating of either PEG-6000 or Polyvinylpyrrolidone (PVP) dissolved in ethanol has been determined to be particularly useful. When initially sprayed onto a balloon, solutions of PEG-6000 and PVP become adherent in high concentrations, however, the stickiness disappears as the solution dries into a film. The water soluble coating has been observed to serve two roles: (i) it acts as a temporary glue to adhere the patch to the delivery system; and (ii) during delivery and when immersed in saline or body liquids, the coating dissolves and releases the patch from the delivery system.
A patch made in accordance with the present invention can be wrapped around the balloon of a balloon catheter in several ways. In a first method, the balloon is totally inflated, sprayed first with a water soluble coating, and then the patch wrapped around the balloon while the water soluble coating is still wet; the balloon then is deflated, dried, and folded. In a second method, the balloon is totally deflated, and may be held under negative pressure (such as applied by a syringe). In this second method, the balloon is sprayed with a water soluble coating, the patch is wrapped around the balloon, and the assembly then is dried and folded. In yet a third method, the balloon is partially inflated and sprayed with a water soluble coating; after which the patch is applied, the balloon is deflated, and the assembly dried.
A water soluble coating of 50 mg/ml of PVP in ethanol was prepared. A 10×40 mm angioplasty balloon was inflated to 4 atm pressure and sprayed with the PVP solution in ethanol. Before the PVP solution dried, a patch prepared as in example 2 above was wrapped around the balloon. The balloon then was deflated and dried. In a second test, a commercial 6×40 mm balloon was unwrapped (from its tight fold) and sprayed with a water soluble coating. A patch prepared as in Example 2 was wrapped around the balloon, and the assembly was dried and folded back again into a tight fold. Alternatively, the patch and balloon may be tightly folded and then dried.
Use of a sheath on the exterior of the patch and balloon catheter was investigated to reduce fluid uptake and premature activation of the patch. It is believed to be important that the sheath be sufficiently close fitting to prevent water from penetrating the gap between the patch and the sheath, so as to prevent the patch from becoming activated prematurely and adhering to the sheath. On the other hand, sliding a tightly fitting sheath over the patch could potentially mechanically damage the patch. In addition, other methods may be employed to prevent water from entering the sheath during delivery, such as by providing pillows on the balloon that permit it to be partially inflated to seal the gap between the balloon catheter and sheath.
A patch prepared as described in Example 2 was wrapped around a 10×40 mm balloon prepared as described in Example 3. A sheath having an inner diameter of about 2.5 mm was easily slid over the patch and the balloon so the patch was not damaged. The balloon was then inflated inside of the sheath to about 2 atm pressure to achieve a tight seal between the balloon and the sheath. During delivery, after the balloon is disposed at the deployment site, negative pressure may be applied to the balloon and the sheath slid away. The balloon may then be inflated to deploy the patch.
The effect of the balloon size on patch delivery was investigated. It was observed that the ratio of balloon diameter to target lumen diameter plays an important role in successful deployment of the patch. In particular, it was observed that the target lumen needs to be sufficiently large enough so the balloon can travel inside it easily, and without significant friction. The lumen also must be sufficiently large that, after the patch is deployed and the balloon is deflated, the patch is not mechanically damaged, e.g., scratched oft when the balloon is being removed. As a further consideration, the artery or lumen must be sufficiently small that inflation of the balloon inside of the lumen creates enough pressure against the luminal wall that the balloon comes fully in contact with the luminal wall over its entire area. It was observed that a ratio of balloon diameter to target lumen diameter of about 1.1:1 provided good results. Accordingly, a 10 mm balloon is believed to be suitable to deliver a patch inside a 9 mm lumen. In addition, folding of the balloon and ratio of the deflated to inflated size of the balloon can impact the results obtained: it was generally found desirable to have the balloon folded to the smallest diameter attainable without damaging the patch.
A patch wrapped around a 10×40 mm balloon as prepared in Example 3 was expanded inside a plastic tube with an inner diameter of about 9 mm, while the plastic tube was immersed in saline solution. In order to deploy the patch, the balloon was expanded to 8 atm and held at that pressure for 10 seconds before being deflated and removed. In a separate test, a similar tube with a patch deployed inside, as described above, was placed in a flow system with a flow rate of about 1200 ml/min. The patch remained intact for the 48 hour duration of the experiment. By comparison, the flow rate in human superficial femoral artery, a potential target site for deployment of the inventive patch, is about 200 ml/min. Similar tests conducted with beef aorta instead of plastic tubing produced comparable results for patch deployment and durability.
Feasibility of use of a patch in accordance with the present invention in a lumen having a side branch was investigated. As discussed above, it is contemplated that a patch constructed in accordance with the present invention could be deployed in a vessel having a side branch, without occluding the side branch. In particular, it is believed that a patch disposed within a target vessel adheres to only those portions of the vessel wall where the patch was brought into apposition by the delivery system. Preferably, the area of the patch facing the side branch opening would remain on the balloon, thus leaving the side branch open.
A patch and delivery system as described in Example 3 was prepared, and the patch was deployed inside a plastic tube having a 3 mm diameter hole drilled on one side of the tube to represent a side branch. After deployment of the patch, the side branch remained open and a 9 mm2 area of the patch was found to have remained on the balloon, corresponding to that portion of the patch that was deployed against the hole.
The feasibility of using a patch of the present invention for drug delivery was investigated. The expectation that it is possible to incorporate any therapeutically useful molecule or ingredient in the formulation of the patch as described herein was tested using patch including PEG-400 and a dye. It is contemplated that therapeutic agents can be incorporated in the formulation in a similar fashion. For example, a desired therapeutic molecule may be dissolved or suspended in an organic solvent and added to either the fibrinogen or the thrombin solutions during the preparation of the patch. In this way the molecule will be trapped inside the fibrin structure and will be delivered over time as the fibrin biodegrades.
Red dye was ground and suspended in ethanol in a ratio of 100 mg/ml. A patch was prepared using the formulation of Example 2, except that 40 μl of the color suspension was added to the fibrinogen suspension prior to mixing with the thrombin solution. After drying, the patch was placed in 4 ml of saline solution and monitored at 2 hour intervals. After 4 hours, it was observed that the red dye had been slowly released into the saline solution. Similar release is expected to occur with a therapeutic agent instead of a dye.
The feasibility of incorporating a radiopaque material into a patch of the present invention to improve visibility under fluoroscopic imaging was investigated. In order to render the patch radiopaque under fluoroscopy, it is desirable to incorporate a radiopaque material in the patch. The radiopaque material may be non-water soluble, such as barium sulfate, or water soluble, such as iodinated contrast agents. These agents can be added to the patch in the same manner as the red dye was added in Example 7.
Barium sulfate often is added to medical devices, usually in a range of 30 wt %, to render such medical devices radiopaque. It was observed that adding such agents at similar weight ratios (30%) of barium sulfate or iodinated contrast agent (iopromide) did not result in observable radiopacity of the patch. It is believed that this result obtained due to the open structure of fibrinogen and the low density of the patch, which was not sufficiently dense to provide the required degree of radiopacity. It was further observed that much higher quantities of the agents were required to produce an acceptable degree of radiopacity. Surprisingly, however, it was found that a patch as formulated above is capable of incorporating significant quantities of radiopaque materials- in some cases multiples of the weight of the fibrinogen and thrombin components, without deterioration in the integrity of the patch. On the other hand, the flexibility, and therefore deliverability of the patch were significantly affected by incorporation of large amounts of foreign particles.
To resolve the foregoing issue, use of a thin strip of a radiopaque patch (that contains high concentration of radiopaque material) was tested as a marker on a patch that did not otherwise contain contrast agent. This approach makes use of the adhering capability of the patch, which maintains its integrity even in the presence of the contrast agent. The result is a biodegradable radiopaque marker that can be adhered to any medical device, including the patch.
A first radiopaque patch was prepared using the formulation of Example 2, except that 100 mg of barium sulfate was added to the fibrinogen suspension prior to mixing with the thrombin solution. A second patch was prepared using the formulation of Example 7, except that only 20 μl of color suspension was added to the fibrinogen suspension prior to mixing with the thrombin solution. The patches were dried tor 3 hours under 30 mm Hg vacuum. A radiopaque marker band was then formed by cutting a rectangular strip having dimensions of 3 mm by 25 mm from the first radiopaque patch. The strip was slightly wetted with water and immediately placed in the middle of a 20 mm by 25 mm rectangular strip of the second patch.
A second radiopaque patch was prepared using the formulation of Example 2, except that 200 mg of iopromide powder was added to the fibrinogen suspension prior to mixing with the thrombin solution. A second patch was prepared using the formulation of Example 7, except that again only 20 μl of color suspension was added to the fibrinogen suspension prior to mixing with the thrombin solution. The patches were dried for 3 hours under 30 mm Hg vacuum. A radiopaque marker band was then formed by cutting a rectangular strip having dimensions of 3 mm by mm from the second radiopaque patch. The strip was slightly wetted with water and immediately placed in the middle of a 20 mm by 25 mm rectangular strip of the second patch.
The two patches prepared above with radiopaque markers were observed under fluoroscope and compared to a bare metal stent. Both patches demonstrated radiopacity comparable to that of the bare metal stent. It was observed that using a non-water soluble contrast agent, such as barium sulfate, in the marker band is advantageous because it has a longer residence time in the marker. Thus, barium sulfate will not dissolve in blood and therefore should remain in the marker for a longer period of time. Over time, the barium sulfate is expected to diffuse out of the fibrin network or be released upon absorption of the fibrin, and then washed away with the blood stream. Iopromide, on the other hand, is water soluble and will dissolve in blood contacting the fibrin matrix. Based on the tests conducted, it is expected that the iopromide patch will lose its radiopacity within 72 hours, while the barium sulfate marker band is expected to persist for a longer interval.
While various illustrative embodiments of the invention are described above, it will be apparent to one skilled in the art that various changes and modifications may be made therein without departing from the invention. The appended claims are intended to cover all such changes and modifications that tall within the true spirit and scope of the invention.
This application is a continuation-in-part application of U.S. patent application Ser. No. 15/656,918, filed on Jul. 21, 2017, which is a continuation patent application of U.S. patent application Ser. No. 15/266,934, filed Sep. 15, 2016, now U.S. Pat. No. 9,713,658, which is a continuation patent application of U.S. patent application Serial No. 14/943,953, filed Nov. 17, 2105, now U.S. Pat. No. 9,446,103, which is a continuation of U.S. patent application Ser. No. 14/788,417, filed Jun.30, 2015, now U.S. Pat. No. 9,192,698, which is a continuation patent application of U.S. patent application Ser. No. 14/054,653, filed Oct. 15, 2013, now U.S. Pat. No. 9,072,681, which is a divisional patent application of U.S. patent application Ser. No. 12/885,306, filed Sep. 17, 2010, now U.S. Pat. No. 8,563,510, which claims the benefit of priority of U.S. Provisional Patent Application Ser. No. 61/243,979, filed Sep. 18, 2009, the contents of each of which are incorporated herein by reference in their entirety. This application is also a continuation-in-part application of U.S. patent application Ser. No. 15/624,304, filed Jun. 15, 2017, which is a continuation patent application of U.S. patent application Ser. No. 15/046,285, filed Feb. 17, 2016, now U.S. Pat. No. 9,682,174, which is a divisional application of U.S. patent application Ser. No. 13/794,355, filed Mar. 11, 2013, now U.S. Pat. No. 9,271,925, the contents of each of which are incorporated herein by reference in their entirety. This application is also related to U.S. patent application Ser. No. 12/885,322, filed Sep. 17, 2010, now U.S. Patent No. 8,529,941, which claims the benefit of priority of U.S. Provisional Patent Application Ser. No. 61/243,979, filed Sep. 18, 2009, the contents of each of which are incorporated herein by reference in their entirety. This application is additionally related to U.S. Patent Application Ser. No. 15/873,829, filed Jan. 17, 2018, published as U.S. Patent Application Publication No. US2018/0200494, which claims the benefit of priority of U.S. Provisional Patent Application Ser. No. 62/447,829, filed Jan. 18, 2017, the contents of each of which are incorporated herein by reference in their entirety.
| Number | Date | Country | |
|---|---|---|---|
| 61243979 | Sep 2009 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 12885306 | Sep 2010 | US |
| Child | 14054653 | US | |
| Parent | 13794355 | Mar 2013 | US |
| Child | 15046285 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 15266934 | Sep 2016 | US |
| Child | 15656918 | US | |
| Parent | 14943953 | Nov 2015 | US |
| Child | 15266934 | US | |
| Parent | 14788417 | Jun 2015 | US |
| Child | 14943953 | US | |
| Parent | 14054653 | Oct 2013 | US |
| Child | 14788417 | US | |
| Parent | 15046285 | Feb 2016 | US |
| Child | 15624304 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 15656918 | Jul 2017 | US |
| Child | 16179540 | US | |
| Parent | 15624304 | Jun 2017 | US |
| Child | 12885306 | US |
